Merck KGaA (MRK) Given a a 103.00 Price Target by Independent Research Analysts


The firm presently has a "neutral" rating on the healthcare company's stock. Independent Research's price objective indicates a potential upside of 32.22% from the stock's current price.



from Biotech News